Back to top
more

Achillion Pharmaceuticals, Inc. (ACHN)

(Delayed Data from NSDQ)

$2.96 USD

2.96
1,311,012

-0.05 (-1.66%)

Updated May 3, 2019 04:00 PM ET

After-Market: $2.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?

by Zacks Equity Research

Celldex Therapeutics, Inc. (CLDX) is expected to report fourth-quarter 2016 results on Mar 4 after market close.

    Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?

    by Zacks Equity Research

    Aerie Pharmaceuticals, Inc. (AERI) is expected to report fourth-quarter 2016 results on Mar 7.

      Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss

      by Zacks Equity Research

      Shares of Achillion Pharmaceuticals, Inc. (ACHN) lost almost 9% on Feb 24, 2017, in spite of the company reporting narrower-than-expected fourth-quarter loss a day before.

        J&J Arm Buys Megadyne, Boosts Electrosurgical Tools Portfolio

        by Zacks Equity Research

        Ethicon Endo-Surgery, Inc. a subsidiary of Johnson & Johnson (JNJ), announced the acquisition of Megadyne Medical Products, Inc., a privately held medical device company.

          Achillion Receives $15M from J&J for HCV Study Enrolment

          by Zacks Equity Research

          Achillion Pharmaceuticals, Inc. (ACHN) announced that it has received a milestone payment of $15 million from Johnson & Johnson's (JNJ) pharma wing, Janssen for the initiation of patient enrollment in the OMEGA-1 phase IIb global study of JNJ-4178.

            Achillion, J&J to Initiate Phase IIb Study on HCV Combo

            by Zacks Equity Research

            Achillion Pharmaceuticals, Inc. (ACHN) announced the initiation of patient dosing in a global phase IIb on JNJ-4178 ??? a triple combination of AL-335, odalasvir (also known as ACH-3102) and J&J's Olysio (simeprevir).

              Kevin Matras headshot

              A Company's First Profit Can Mean Big Profits to Investors

              by Kevin Matras

              Kevin Matras screens for companies showing their 'first' profit, and explains why they are ones to watch. Highlighted stocks include ACHN, OPK, ENT, LC and CUDA.